| INTRODUC TI ON
One of the most common malignant cancers namely lung cancer, with an estimated 1.8 million new cases merely occurring in 2012, accounts for about 13% of total cancer diagnoses throughout the world. 1 In China, lung cancer accounts for most of the emerging cancers and is the leading cause of mortality of all cancers. 2 Majority of patients have been diagnosed in the middle stage or late stage, and thus are unable to receive surgical treatment. Five years relative survival rate of lung cancer is <15% and patients with symptoms are even lower. 3 However, the survival rate of patients with lung cancer may increase and the prognosis is obviously improved when surgical treatment is proceeding at early stage. 4 Therefore, early diagnosis is essential for the improvement of the survival rate of lung cancer patients. There are several methods to make the diagnosis for lung cancer, such as chest radiographs, tumor markers, and pathological examinations. Radiographic inspection is an important test method for the diagnosis of lung cancer, but it is difficult to distinguish benign pulmonary nodules from malignant tumors. 5 Pathological examination needs to take biopsy samples, which is invasive and has the risk of injury. Despite high sensitivity of pathological examination, false-negative results may be obtained due to the limitation for the position from where the samples were taken. 6 Tumor markers, commonly used as auxiliary index for di- modifications shown in Figure 2 . The results were read by HD-2001A/LU-07 biochip reader (SHMY HealthDigit Biochips Co., Ltd.
| Sample collection and detection
Shanghai, China).
| Detection indicator and normal reference range
Detection indicator and normal reference range were as follows:
CA125 < 35 U/mL, CA199 < 35 U/mL, Ferritin < 219 ng/mL (female) and 322 ng/mL (male), CA153 < 35 U/mL, CA242 < 20 U/ mL, CEA <5 ng/mL, AFP < 20 ng/mL, NSE < 13 ng/mL, PSA < 5 ng/ mL, f-PSA < 1 ng/mL, HGH < 7.5 ng/mL, and β-HGH < 3 mIU/mL.
Except Ferritin, if the tested result of any other tumor markers is higher than the normal reference range, the detected tumor marker can be defined as positive, otherwise negative.
| Statistical methods and data analysis
Statistical analysis was performed using SPSS Statistics 19.0 (SPSS, Inc., Chicago, IL, USA). The difference of rate between groups was calculated by Chi-square, and the level of serum markers between different lung cancers characteristics was compared by Student's t test. P < .05 was considered significant.
| RE SULTS

| Comparison of the positive detection rates among the 3 groups
Positive rates of tumor markers among the 3 groups (namely lung cancer, hospitalized patients, and control) were included in the present study (shown in Table 1 ). The positive rate of the lung cancer group was 77.23%, the hospitalized patients' group was 13.84% and the control group was 9.76%. Compared with the hospitalized patients and control group, the positive rate of the lung cancer group was significantly higher and calculated by χ 2 test (χ 2 = 239.1, P < .01; χ 2 = 300.0, P < .01). The positive rate of CA199, NSE, CEA, CA242, Ferritin, and CA153 were significantly higher in patients with lung cancer than those with benign disease or apparently healthy people (P < .05), but not in β-HCG, AFP, PSA, and HGH (P > .05). In addition, there was no significant difference in f-PSA or CA125 between the cancer group and the hospitalized patients (P > .05).
| Serum level of C-12 tumor markers among the 3 groups
Serum levels of the tumor markers are shown in Table 2 . Compared with the hospitalized patients and control, serum levels of CA199, CEA, CA242, β-HCG, AFP, CA125, and CA153 in cancer patients were significantly higher (P < .05). There was no significant difference in the concentration of β-HCG, PSA, or HGH among the 3 groups (P < .05).
| Positive rates in different lung cancer based on cytological diagnosis and/or IHC
Positive rates of tumor markers among different lung cancer based on cytological diagnosis and/or IHC are shown in Table 3 . In detail, the positive rates of adenocarcinoma, squamous cell carcinoma, and small-cell carcinoma with joint detection were successively 69.92%, 60.00%, and 70.37%. Calculated by χ 2 test, the positive rates of CEA, CA242, CA125, and CA153 in adenocarcinoma were apparently higher than that of squamous cell carcinoma, and the positive rate of CA125 was obviously higher than that of squamous cell carcinoma (P < .05). In the same row, different number (eg, a and b, b and c, a and c) showed there was significant difference between the lung cancer, hospitalized and control (P < .05). In the same row, the same number (eg, a and a, b and b, c and c) showed there was no significant difference between the lung cancer, hospitalized and control (P > .05).
TA B L E 2 Serum level of C-12 tumor markers in the 3 groups (x ± s)
| Serum level of C-12 tumor markers among 3 different lung cancers
Concentration of C-12 tumor markers of 3 different lung cancer is shown in Table 4 . It showed a significant increase in the concentration of CA199, CEA, CA242, and CA125 in adenocarcinoma compared with squamous cell carcinoma and small-cell carcinoma (P < .05). In squamous cell carcinoma, the level of CA153 was higher than small-cell carcinoma (P < .05).
| D ISCUSS I ON
Lung cancer has been the most common and lethal malignant several malignancies, such as breast cancer, lymphoma, and metastatic disease. [13] [14] [15] Hence, the level of ferritin may not be used to distinguish the lung cancer from the benign pulmonary. NSE is a subunit of enolase enzyme found mainly in neurons and neuroendocrine cells and is a marker of SCLC. 16 CA125 is a glycoprotein found in epithelia ovarian carcinoma but not in normal adult ovarian tissues. 17 In the diagnostic of lung cancer, it was reported that the sensitivity of CA125 was 44.25%. 18 In the present study, the positive rate of CA125 was 70.98% in the lung cancer group, but in hospitalized patients, a high positive rate 74.21% was also observed.
So, the CA125 may not be used as a valuable diagnostic marker for the screen of lung cancer with false positive. CEA is a glycoprotein that normally produced during fetal development but is not present in the blood of healthy people. Usually, CEA is considered to be a tumor marker in colorectal cancer or be associated with the prognostic of lung cancer. 9 Recently, CEA has become the marker of choice for lung adenocarcinomas. 19 In this study, the sensitivity of CEA was 61.16% in the lung cancer and 61.76% in lung adenocarcinomas. CA199 is a glycoprotein and exists as a ganglioside on tumor cell. CA199 is primarily used for the detection of cancer pancreas and gastrointestinal cancer. 20, 21 It was reported that combination of CEA and CA199 can reach a sensitivity of 91.5% in the diagnostic of lung adenocarcinoma-associated malignant pleural effusions (LAMPEs). 22 In the present study, the sensitivity of the combination TA B L E 3 Positive rate of total and C-12 tumor markers in the group of the lung cancer (%) In the same column, different number (eg, a and b, b and c, a and c) showed there was significant difference between the adenocarcinoma, squamous cell carcinoma and small cell carcinoma group (P < .05). In the same column, the same number (eg, a and a, b and b, c and c) showed there was no significant difference between the adenocarcinoma, squamous cell carcinoma and small cell carcinoma group (P > .05).
of CEA and CA199 was 69.64% in the lung cancer and 71.43% in adenocarcinoma.
In summary, the C-12 multiple tumor protein-chip detective system has acceptable sensitivity in the early screen for lung cancer, but cannot be used as a confirmed method.
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